A Phase 2 interventional study of 40 mg CBL-514 and 60 mg CBL-514 in Cellulite, sponsored by Caliway Biopharmaceuticals Co., Ltd.. Completed at 2 sites in United States. Open to female participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Caliway Biopharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study to assess the efficacy and safety of CBL-514 in participants with Edematous Fibrosclerotic Panniculopathy (EFP) cellulite.
This Phase 2a study has an integrated design consisting of a single ascending dose (SAD) part in Stage 1 followed by a single-arm design in Stage 2. The Stage 1 will include a total of 12 participants enrolled in 3 sequential escalating CBL-514 dose groups.The groups will be open label and each group will enroll 4 participants.
Eligible participants will be sequentially assigned to receive 1 course of allocated CBL-514 dose administered by subcutaneous injection on both sides of the posterolateral thighs.
71 studies on the registry are indexed under Cellulite; 3 are open to participants now.
This study's enrollment of 12 is below the median of 34 across 65 interventional studies indexed under Cellulite.
Browse Cellulite studies →Caliway Biopharmaceuticals Co., Ltd. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant has both sides of posterolateral thighs assessed according to the modified Hexsel CSS (A) number of evident depressions, (B) depression depth scale, and (C) morphological appearance of skin surface alterations. On assessment by the modified Hexsel CSS, the participant scores at least 4 and no greater than 8 at Screening and Day 1.
The total score must contain:
Exclusion Criteria:
Female participant of who is not willing to commit to an acceptable regimen with her partner from the time of Screening and throughout study participation until 90 days after the last IP dose, or who is currently pregnant or lactating.
Note: females who are not of childbearing potential are not required to use contraception. Females not of childbearing potential are defined as those who have been surgically sterilized (hysterectomy or bilateral oophorectomy) or who are (defined as aged at least 50 years old with ≥ 12 months of amenorrhea and a follicle-stimulating hormone [FSH] > 30 IU/L at Screening).
Participant has abnormal skin or local skin conditions at the treatment area, which in the opinion of the Investigator (or designee), is inappropriate to participate in the study. This includes but is not limited to any of the following:
Participant who has had the following surgical or aesthetic procedures:
Participating is requiring continual use of the following therapeutic agents during the study: terfenadine, buspirone, fexofenadine, any medication that is known to strongly inhibit or induce CYP enzymes, sensitive CYP substrates or drugs with narrow therapeutic index, which in the opinion of the Investigator (or designee), may affect the evaluation of the product or place the participant at undue risk.
If a participant needs to use the above-mentioned therapeutic agents during the study for any reason, these therapeutic agents should not be used at least for 2 days before dosing and until 1 day after dosing.
Participant with any renal impairment, defined as abnormal serum creatinine, and urea > 1.5 × ULN or estimated (eGFR) \< 90 mL/min/1.73 m2. Participants who are currently on dialysis should be excluded.
Participants with an eGFR ≥ 60 and \< 90 mL/min/1.73 m2 at Screening should be evaluated by the Investigator to exclude pre-existing renal disease or associated dysfunction. If mild decrease in eGFR is assessed by the Investigator as not clinically significant or not related to dysfunction, the participants may be eligible upon the Investigator's assessment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 40 mg CBL-514
Drug: 60 mg CBL-514
Drug: 80 mg CBL-514
CBL-514 will be administered at the raised area of cellulite.
CBL-514 will be administered at the raised area of cellulite.
CBL-514 will be administered at the raised area of cellulite.
Evaluation of the Improvement of Edematous Fibrosclerotic Panniculopathy (EFP) Measured by Cellulite Severity Scale From Baseline Following Administration of 1 Course of CBL-514.
Change in total scores from baseline according to the modified Hexsel cellulite severity scale (CSS) at Week 2 and Week 4 based on (A) number of evident depressions, (B) depression depth scale, and (C) morphological appearance of skin surface alterations. (A) Number of evident depressions: '0' = None/no depressions '1' = 1 to 4 depressions are visible '2' = 5 to 9 depressions are visible '3' = 10 or more depressions are visible (B) Depth of depressions: '0' = No depressions '1' = Superficial depressions '2' = Medium depth depressions '3' = Deep depressions (C) Morphological appearance of skin surface alterations: '0' = No raised areas '1' = 'Orange peel' appearance '2' = 'Cottage cheese' appearance '3' = 'Mattress' appearance The total score of (A), (B) and (C) will determine the cellulite severity level as follows : 0 = None 1-3 = Mild 4-6 = Moderate 7-9 = Severe
Time frame: From baseline to Week 4
Percentage of Participants' Thighs That Achieve at Least 1-level Severity Improvement From Baseline Following Administration of 1 Course of CBL-514
Percentage of participants' thighs that achieve at least 1-level severity improvement determined by the total scores of modified Hexsel CSS at Week 2 and Week 4 compared to baseline.
Time frame: From baseline to Week 4
Number of Participants With TEAEs Following Administration of 1 Course of CBL-514.
Number of participants with TEAEs following administration of 1 course of CBL-514.
Time frame: from Day 1 up to Week 4
Number of TEAEs Following Administration of 1 Course of CBL-514
Number of TEAEs following administration of 1 course of CBL-514
Time frame: From Day 1 up to Week 4
Number of Participants With Adverse Events of Special Interest
Number of participants with adverse events of special interest
Time frame: From Day 1 up to Week 4
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests
Laboratory tests include assessment of hematology, biochemistry, coagulation, and urinalysis tests
Time frame: From Day 1 up to Week 4
Number of Participants With Clinically Significant Abnormalities in Physical Examination
Physical examinations include assessment of 12-lead electrocardiogram parameters and vital signs
Time frame: From Day 1 up to Week 4
Number of Participants Who Used Concomitant Medications to Treat Treatment-emergent Adverse Events
Number of participants who used concomitant medications to treat treatment-emergent adverse events
Time frame: From Day 1 up to Week 4
All 12 participants enrolled in the study received a single treatment of CBL-514 in 3 sequential escalating doses on the postlateral thighs (administered as multiple subcutaneous injections) on Day 1 only.
| Milestone | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| Started | 4 | 4 | 4 |
| Completed | 4 | 3 | 4 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
Change in total scores from baseline according to the modified Hexsel cellulite severity scale (CSS) at Week 2 and Week 4 based on (A) number of evident depressions, (B) depression depth scale, and (C) morphological appearance of skin surface alterations. (A) Number of evident depressions: '0' = None/no depressions '1' = 1 to 4 depressions are visible '2' = 5 to 9 depressions are visible '3' = 10 or more depressions are visible (B) Depth of depressions: '0' = No depressions '1' = Superficial depressions '2' = Medium depth depressions '3' = Deep depressions (C) Morphological appearance of skin surface alterations: '0' = No raised areas '1' = 'Orange peel' appearance '2' = 'Cottage cheese' appearance '3' = 'Mattress' appearance The total score of (A), (B) and (C) will determine the cellulite severity level as follows : 0 = None 1-3 = Mild 4-6 = Moderate 7-9 = Severe
| score on a scale | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| Baseline | 6.8 ± 1.3 | 6.1 ± 1.6 | 7.8 ± 0.7 |
| Week 2 | 4.6 ± 0.7 | 4.9 ± 1.8 | 5.8 ± 0.5 |
| Week 4 | 4.8 ± 0.7 | 4.6 ± 1.8 | 5.1 ± 1.1 |
| Change at Week 2 from Baseline | -2.1 ± 1.0 | -1.3 ± 0.9 | -2.0 ± 0.9 |
| Change at Week 4 from Baseline | -2.0 ± 0.9 | -1.5 ± 0.9 | -2.6 ± 1.5 |
Percentage of participants' thighs that achieve at least 1-level severity improvement determined by the total scores of modified Hexsel CSS at Week 2 and Week 4 compared to baseline.
| thigh | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| Week 2 | 5 | 5 | 7 |
| Week 4 | 5 | 7 | 7 |
Number of participants with TEAEs following administration of 1 course of CBL-514.
| Participants | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| Mild | 2 | 3 | 2 |
| Moderate | 1 | 0 | 0 |
Number of TEAEs following administration of 1 course of CBL-514
| event | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| Mild | 18 | 22 | 21 |
| Moderate | 2 | 0 | 0 |
Number of participants with adverse events of special interest
| Participants | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| Number of Participants With Adverse Events of Special Interest | 0 | 0 | 0 |
Laboratory tests include assessment of hematology, biochemistry, coagulation, and urinalysis tests
| Participants | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| Hematology | 0 | 0 | 0 |
| Biochemistry | 0 | 0 | 0 |
| Coagulation | 0 | 0 | 0 |
| Urinalysis tests | 0 | 0 | 0 |
Physical examinations include assessment of 12-lead electrocardiogram parameters and vital signs
| Participants | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| 12-lead Electrocardiogram | 0 | 0 | 0 |
| Vital signs | 0 | 0 | 0 |
Number of participants who used concomitant medications to treat treatment-emergent adverse events
| Participants | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| Number of Participants Who Used Concomitant Medications to Treat Treatment-emergent Adverse Events | 1 | 1 | 1 |
Collected over from baseline until the end of follow-up, up to 4 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CBL-514 40mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| CBL-514 60mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| CBL-514 80mg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Event | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg |
|---|---|---|---|
| Injection site bruisingGeneral disorders | 2/4 | 3/4 | 1/4 |
| Injection site erythemaGeneral disorders | 2/4 | 2/4 | 1/4 |
| Injection site swellingGeneral disorders | 2/4 | 2/4 | 1/4 |
| Injection site painGeneral disorders | 0/4 | 2/4 | 2/4 |
| Injection site pruritusGeneral disorders | 2/4 | 1/4 | 1/4 |
| Injection site warmthGeneral disorders | 1/4 | 1/4 | 2/4 |
| Injection site indurationGeneral disorders | 0/4 | 1/4 | 1/4 |
| Injection site discolourationGeneral disorders | 1/4 | 0/4 | 0/4 |
| Age, Continuous(years) | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg | Total |
|---|---|---|---|---|
| Mean | 51.5 ± 11.2 | 49 ± 8.9 | 51.3 ± 16.6 | 50.6 ± 11.5 |
| Sex: Female, Male(Participants) | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg | Total |
|---|---|---|---|---|
| Female | 4 | 4 | 4 | 12 |
| Male | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 2 |
| White | 3 | 3 | 4 | 10 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 3 | 4 | 4 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg | Total |
|---|---|---|---|---|
| United States | 4 | 4 | 4 | 12 |
| Childbearing potential(Participants) | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg | Total |
|---|---|---|---|---|
| Yes | 2 | 3 | 2 | 7 |
| No | 2 | 1 | 2 | 5 |
| Weight(kilograms) | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg | Total |
|---|---|---|---|---|
| Mean | 73.10 ± 2.44 | 73.45 ± 11.93 | 66.03 ± 9.09 | 70.86 ± 8.70 |
| Height(centimeters) | CBL-514 40mg | CBL-514 60mg | CBL-514 80mg | Total |
|---|---|---|---|---|
| Mean | 160.00 ± 4.64 | 167.03 ± 9.45 | 159.35 ± 3.83 | 162.13 ± 6.89 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Caliway Biopharmaceuticals Co., Ltd. →